Eravac
Rabbit haemorrhagic disease vaccine (inactivated)
Table of contents
Overview
Eravac is a veterinary vaccine used in rabbits to reduce death due to the rabbit haemorrhagic disease (RHD), caused by the variant of RHD virus called RHD type 2 (RHDV2). It is usually a fatal disease resulting in the formation of blood clots.
RHD type 2 virus differs from the classic form of RHD virus since the course of disease is more prolonged, death occurs later and over a longer period and is more severe in young rabbits.
Eravac contains inactivated rabbit haemorrhagic disease type 2 virus, strain V-1037, as the active substance.
Authorisation details
Product details | |
---|---|
Name |
Eravac
|
Agency product number |
EMEA/V/C/004239
|
Active substance |
Inactivated rabbit haemorrhagic disease type 2 virus (RHDV2), strainV-1037
|
International non-proprietary name (INN) or common name |
Rabbit haemorrhagic disease vaccine (inactivated)
|
Species |
Rabbits
|
Anatomical therapeutic chemical veterinary (ATCvet) codes |
QI08AA
|
Publication details | |
---|---|
Marketing-authorisation holder |
Laboratorios Hipra, S.A.
|
Revision |
6
|
Date of issue of marketing authorisation valid throughout the European Union |
22/09/2016
|
Contact address |
Avda. La Selva, 135 |
Product information
16/08/2021 Eravac - EMEA/V/C/004239 - II/0006
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Therapeutic indication
For active immunisation of rabbits from the age of 30 days to reduce mortality caused by the rabbit haemorrhagic disease type 2 virus (RHDV2)